Management of inherited thrombophilia: Guide for genetics professionals

Clinical Genetics

Volumn 81, Issue 1, 2012, Pages 7-17

  Varga, E A ^a,b   Kujovich, J L ^c  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Factor V Leiden; Management; Prevention; Thrombophilia; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; ESTROGEN; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN A; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGING; BLOOD CLOTTING FACTOR DEFICIENCY; BREAST CANCER; DISEASE PREDISPOSITION; FAMILY HISTORY; GENETIC DISORDER; HEALTH CARE PERSONNEL; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ANTITHROMBIN III; DISEASE MANAGEMENT; EPISTASIS, GENETIC; EVIDENCE-BASED PRACTICE; FACTOR V; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC TESTING; GENOTYPE; HEALTH PERSONNEL; HUMANS; MUTATION; PROTEIN S; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 83355166854     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01746.x     Document Type: Review

References (71)

1. EGAPP Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 2011: 13(1): 67-76.
2. Varga E. Inherited thrombophilia: key points for genetic counseling. J Genet Couns 2007: 16(3): 261-277.
3. Baglin T, Gray E, Greaves M et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010: 149(2): 209-220.
4. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997: 277(16): 1305-1307. Epub 23 April 1997.
5. Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med 2009: 11(2): 114-128.
6. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011: 13(1): 1-16.
7. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005: 1-12. Epub 24 November 2005.
8. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007: 67 (10): 1429-1440.
9. Bauer KA. Duration of anticoagulation: applying the guidelines and beyond. Hematology Am Soc Hematol Educ Program 2010: 2010: 210-215.
10. Moll S. Thrombophilias - practical implications and testing caveats. J Thromb Thrombolysis 2006: 21 (1): 7-15.
11. Pereira AC, Schettert IT, Morandini Filho AA, Guerra-Shinohara EM, Krieger JE. Methylenetetrahydrofolate reductase (MTHFR) c677t gene variant modulates the homocysteine folate correlation in a mild folate-deficient population. Clin Chim Acta 2004: 340 (1-2): 99-105. Epub 22 January 2004.
12. den Heijer M, Willems HP, Blom HJ et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007: 109 (1): 139-144.
13. Morange PE, Bezemer I, Saut N et al. A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. Am J Hum Genet 2010: 86 (4): 592-595.
14. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006: 145 (11): 807-815.
15. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994: 84 (4): 1031-1035.
16. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995: 85 (12): 3518-3523.
17. van Boven HH, Vandenbroucke JP, Briet E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999: 94 (8): 2590-2594. Epub 9 October1999.
18. Hellmann E, Leslie N, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 2003: 1 (11): 2335-2339.
19. Langlois N, Wells P. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003: 90 (1): 17-26.
20. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002: 162 (10): 1182-1189.
21. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006: 295 (9): 1050-1057.
22. DeSancho MT, Berlus N, Christos PJ, Rand J. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. Blood Coagul Fibrinolysis 2010: 21 (1): 11-15. Epub 29 May 2009.
23. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009: 169 (6): 610-615. Epub 25 March 2009.
24. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005: 293 (6): 715-722. Epub 11 February 2005.
25. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008: 133 (6 Suppl.): 381S-453S.
26. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005: 3 (11): 2471-2478. Epub 26 October 2005.
27. Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008: 6 (1): 70-75. Epub 9 November 2007.
28. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000: 160 (22): 3415-3420.
29. Eekhoff EM, Rosendaal FR, Vandenbroucke JP. Minor events and the risk of deep venous thrombosis. Thromb Haemost 2000: 83 (3): 408-411.
30. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000: 83 (6): 817-821. Epub 15 July 2000.
31. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002: 162 (11): 1245-1248.
32. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000: 343 (24): 1758-1764.
33. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am 1986: 68 (1): 146-150.
34. Wåhlander K, Larson G, Lindahl TL et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 2002: 87 (4): 580-585.
35. Joseph JE, Low J, Courtenay B, Neil MJ, McGrath M, Ma D. A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. Br J Haematol 2005: 129 (1): 87-92.
36. Paffrath T, Wafaisade A, Lefering R et al. Venous thromboembolism after severe trauma: incidence, risk factors and outcome. Injury 2010: 41 (1): 97-101.
37. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med 2008: 168 (1): 21-26. Epub 16 January 2008.
38. Trenor CC, Chung RJ, Michelson AD et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 2011: 127 (2): 347-357.
39. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994: 344 (8935): 1453-1457.
40. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999: 19 (3): 700-703.
41. van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007: 167 (3): 282-289.
42. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995: 346 (8990): 1593-1596. Epub 16 December 1995.
43. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010: 81 (5): 408-413.
44. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002: 65 (3): 187-196.
45. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998: 57 (5): 315-324.
46. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010: 30 (11): 2297-2300.
47. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010: 8 (5): 979-986.
48. Canonico M, Fournier A, Carcaillon L et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010: 30 (2): 340-345.
49. Herrington DM, Vittinghoff E, Howard TD et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002: 22 (6): 1012-1017.
50. Straczek C, Oger E, Yon de Jonage-Canonico MB et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005: 112 (22): 3495-3500.
51. Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004: 292 (13): 1573-1580.
52. Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of Factor V Leiden and prothrombin G20210->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 2006: 98 (13): 904-910. Epub 5 July 2006.
53. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003: 21 (19): 3588-3593. Epub 27 September 2003.
54. Garber JE, Halabi S, Tolaney SM et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010: 102 (13): 942-999. Epub 18 June 2010.
55. James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program 2009: 277-285.
56. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999: 54 (4): 265-271.
57. Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 2010: 8 (11): 2443-2449. Epub 26 August 2010.
58. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003: 90 (1): 77-85. Epub 24 July 2003.
59. Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006: 132 (2): 171-196.
60. Friederich PW, Sanson BJ, Simioni P et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996: 125 (12): 955-960.
61. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86 (3): 800-803. Epub 5 October 2001.
62. Bates S, Greer I, Pabinger I, Sofaer S, Hirsh J, Physicians ACoC. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008: 133 (6 Suppl.): 844S-886S.
63. Practice bulletin no. 113: inherited thrombophilias in pregnancy. Obstet Gynecol 2010: 116 (1): 212-222.
64. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005: 118 (9): 978-980.
65. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007: 139 (2): 289-296.
66. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009: 151 (3): 180-190.
67. Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol 2011: 152 (1): 31-34.
68. Martinelli I, Taioli E, Battaglioli T et al. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med 2003: 163 (22): 2771-2774.
69. Lijfering WM, Brouwer JL, Veeger NJ et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009: 113 (21): 5314-5322.
70. Simioni P, Sanson BJ, Prandoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999: 81 (2): 198-202. Epub 4 March 1999.
71. Segal JB, Brotman DJ, Necochea AJ et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009: 301 (23): 2472-2585. Epub 18 June 2009.